Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers. The PUMA Study

NCT05131919 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT05131919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05131919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers. The PUMA Study
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 22, 2022
Completion date
July 31, 2031
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer